This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. (Clinical trial summary from the National Cancer Institute's PDQ database) Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. G3139 (antisense Bcl-2 oligonucleotide) may increase the effectiveness of carboplatin and paclitaxel by making tumor cells more sensitive to the drugs.This is a Phase I trial to study the effectiveness of combining carboplatin and paclitaxel with G3139 in treating patients who have advanced solid tumors.Patients will receive a 7-day continuous infusion of G3139. They will also receive a 3-hour infusion of paclitaxel followed by an infusion of carboplatin on Day 4. Treatment may be repeated every 3 weeks for as long as benefit is shown.
Showing the most recent 10 out of 459 publications